Compare GAIA & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | GLSI |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7M | 123.9M |
| IPO Year | 1999 | 2020 |
| Metric | GAIA | GLSI |
|---|---|---|
| Price | $3.72 | $17.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $39.00 |
| AVG Volume (30 Days) | 133.7K | ★ 373.1K |
| Earning Date | 11-03-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,622,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $11.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.80 | N/A |
| 52 Week Low | $2.93 | $7.78 |
| 52 Week High | $6.39 | $17.99 |
| Indicator | GAIA | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 87.38 |
| Support Level | $3.39 | $13.11 |
| Resistance Level | $4.05 | $13.76 |
| Average True Range (ATR) | 0.27 | 1.48 |
| MACD | 0.05 | 0.69 |
| Stochastic Oscillator | 43.96 | 91.51 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.